A COX-1 inhibitor Aspirin reduced Ponatinib-induced death and cardiac dysfunction in zebrafish larvae. (A) Survival curves of 1 dpf zebrafish larvae were treated with 0.1 % DMSO or 10 ?M Ponatinib or co-treated Aspirin at indicated concentrations and 10 ?M Ponatinib for 3 days (n=15). Data are represented as mean ± SEM. ###P < 0.005 versus control group; ***P < 0.005 vs. Ponatinib group. (B) Body length of 4 dpf zebrafish (n=7). Data are represented as mean ± SEM. ###P < 0.005 versus control group; **P < 0.01 and ***P < 0.005 vs. Ponatinib group. (C) Heart rate of 4 dpf zebrafish (n=10). Data are represented as mean ± SEM. ###P < 0.005 versus control group; ***P < 0.005 vs. Ponatinib group. (D) 1 dpf Tg (cmlc2: GFP) transgenic zebrafish larvae were treated with 0.1 % DMSO or 10 ?M Ponatinib or co-treated Aspirin at indicated concentrations and 10 ?M Ponatinib for 3 days (n=10). The represented images of the heart in different groups. (E) The pericardial edema area and (F) SV-BA distance in different groups were quantified. Data are represented as mean ± SEM. ###P < 0.005 versus control group; ***P < 0.005 vs. Ponatinib group. (G) The mRNA levels of, cacna1c, cacn2d2a, cacna2d2b, and cacna3b in 4 dpf zebrafish were determined by RT-qPCR. Data are represented as mean ± SEM. ##P < 0.01 and ###P < 0.005 versus control group; **P < 0.01 and ***P < 0.005 vs. Ponatinib group.
|
